The prevalence of hepatocellular carcinoma (HCC) is increasing worldwide, whereas that of
most other cancers is decreasing. Non-alcoholic fatty liver disease (NAFLD), which has …

Lenvatinib is the first target drug approved for advanced hepatocellular carcinoma (HCC).
However, the development of drug resistance is common, and the mechanisms of lenvatinib …

Chimeric antigen receptor (CAR) therapy is a promising immunotherapeutic strategy for
treating multiple refractory blood cancers, but further advances are required for solid tumor …

Patients with advanced hepatocellular carcinoma (HCC) have historically had few options
and faced extremely poor prognoses if their disease progressed after standard-of-care …

Hepatocellular carcinoma is a common cancer with a poor prognosis, associated with high
economic costs and a significant burden of disease. While it is often asymptomatic in the …

Hepatocellular carcinoma (HCC) is a major public health burden in Hong Kong, and chronic
hepatitis B is the most common HCC etiology in our region. With the high case load …

Hepatocellular carcinoma (HCC) is a common complication in patients with chronic liver
disease and leads to significant morbidity and mortality. Liver disease and liver cancer are …

Hepatocellular carcinoma (HCC) is a deadly and burdensome form of liver cancer with an
increasing global prevalence. Its course is unpredictable as it frequently occurs in the …

Simple Summary Decompensated patients with hepatocellular carcinoma (HCC) are a wide
patient category with limited therapeutic options, and are often excluded from existing trials …

Hepatocellular carcinoma (HCC) is the most frequent primary liver cancer and forms a major
global health problem. In fact, HCC currently ranks as the fourth most common cause of …